Tenon Medical (TNON) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 21% year-over-year to $901,000, driven by a 7% increase in Catamaran System procedures and expanded sales operations across five U.S. regions.

• Gross profit for Q2 2024 was $470,000 (52% margin), up 142% from $194,000 (26% margin) in Q2 2023, marking four consecutive quarters of positive gross profit.

• Net loss for Q2 2024 narrowed to $3.8 million from $4.3 million in Q2 2023, reflecting improved gross margin and reduced operating expenses.

• Cash and cash equivalents totaled $2 million as of June 30, 2024, with no outstanding debt.

• CFO transition announced, with Jay Hansen appointed interim Principal Accounting Officer following Steve Van Dick's retirement.

Financial highlights

• Q2 2024 revenue was $901,000, up from $743,000 in Q2 2023; six-month revenue was $1.6 million, up 38% year-over-year.

• Gross margin for Q2 2024 was 52%, up from 26% in Q2 2023; six-month gross margin was 58%, up from 13% in the prior year period.

• Operating expenses for Q2 2024 were $4.3 million, down 4% year-over-year; six-month operating expenses were $8.3 million, down from $9.4 million.

• Net loss per share was $1.02 in Q2 2024, compared to $3.28 in Q2 2023.

• Weighted average shares outstanding for Q2 2024: 3.75 million.

Outlook and guidance

• Expectation of continued operating losses and negative cash flows as commercialization and product development continue.

• Existing cash is insufficient to fund operations for the next 12 months; additional capital will be sought via equity, debt, or collaborations.

• Anticipate that upcoming post-market clinical data will drive further adoption and growth in the second half of 2024.

• Ongoing cadence of clinical publications expected as patient follow-up milestones are reached.

• Substantial doubt exists regarding the company's ability to continue as a going concern over the next year.